Prokarium
Blood & Organ Banks · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
London Bioscience Innovation cen 2 Royal...Website
www.prokarium.comRevenue
<$5 MillionIndustry
ZI Rank: 3
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
2
2
1
3
About Prokarium
Prokarium is a biopharmaceutical company specializing in microbial immunotherapy, utilizing a proprietary strain of bacteria to develop innovative cancer treatments. Their lead program focuses on bladder cancer, aiming to transform treatment paradigms and address significant unmet medical needs. The company also offers a Living Cures platform that delivers programmable therapeutics for various cancers, enhancing the efficacy of existing immunotherapies. Prokarium targets healthcare providers and patients seeking advanced cancer treatment options.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Prokarium your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Prokarium is spiking on competitors!
Earning: See what the market has to say on Prokarium recently announced quarterly report
Check if Prokarium has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Prokarium launches new products
Congratulate Masked Content for being promoted to Masked Content at Prokarium
Click to see if Prokarium had a recent Job posting/layoffs
Prokarium, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Prokarium has new funding data
Recommended Actions
Find VP level buyers at Prokarium
Find more new buyers
Compare Similar Companies to Prokarium
Compare insights from companies similar to Prokarium, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Prokarium
<$5M
11-50
Private
$66.7M
2012
N/A
Company Profile Activity
Activity Insights
Prokarium is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Prokarium is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Prokarium.
Prokarium financials insights
Gather financial insights about Prokarium, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$10M
2019
Other Financing Round
$5.7M
2020
Series B
$21M
2023
Other Financing Round
$30M
Prokarium Tech Stack
A closer look at the technologies used by Prokarium
See more technologies
Most Recent Scoops
Lateral Move
Executive Move
Executive Moves, Lateral Move, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Project
Product Management, Intellectual Property, Legal Affairs, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Regulations
Funding
Promotion
Executive Move
Prokarium News & Media
Prokarium Expands IP Portfolio With Two New U.S. Patents Strengthening Its Position in Bladder Cancer
LONDON--(BUSINESS WIRE)--Prokarium, a biopharmaceutical company developing innovative cancer treatments, today announced the receipt of two Notices of Allowance from the United States Patent and Trademark Office (USPTO). These patents, covering applications Nos. 17/752,707 and 18/559,543, strengthen Prokarium’s mission to develop innovative, scalable therapies that address critical gaps in cancer treatment. Application No. 17/752,707 protects the co-administration of Prokarium’s proprietary SalProkarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial
LONDON--(BUSINESS WIRE)--Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic biology, today announces the dosing of the first patient in their PARADIGM-1 Phase I/Ib clinical trial in non-muscle invasive bladder cancer (NMIBC) patients (NCT06181266). The study is being conducted at multiple clinical sites across the United States and will initially evaluate the safety of a single intravesical administration of their investigational immProkarium Achieves Major Milestone with FDA's IND Approval for Bladder Cancer Program
LONDON--(BUSINESS WIRE)--Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create novel cancer treatments, today announces that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application for their immunotherapy ZH9. The approval enables initiation of the clinical development program for ZH9 in the U.S., focusing on patients with non-muscle invasive bladder cancer. "The FDA’s approval of our IND applicatMicrobial Immunotherapy Company Prokarium Raises $30M On Heels Of Ginkgo Bioworks Partnership
the next time you think Salmonella, think Prokarium. These bacteria may cause food poisoning in one form, but engineered the right way can become living medicine — turning not fuel into fire but fire into fuel.
Read more news
Top Blood & Organ Banks Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Prokarium
Sign Up For FreeTo access detailed company insights
Prokarium is a biopharmaceutical company specializing in microbial immunotherapy, utilizing a proprietary strain of bacteria to develop innovative cancer treatments. Their lead program focuses on bladder cancer, aiming to transform treatment paradigms and address significant unmet medical needs. The company also offers a Living Cures platform that... Read More
